# CurePSP Leads Bipartisan Briefing to Boost PSP, CBD, and MSA Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/advancing-rare-neurodegenerative-diseases-research/ > **Published:** 2026-03-30T14:03:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:57-04:00 > **Clinical Summary:** Explore how rare neurodegenerative diseases research is advancing through bipartisan congressional advocacy for PSP, CBD, and MSA funding. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Neurodegenerative DiseaseMovement DisordersResearch AdvocacyRare DiseasePolicy Why This Matters Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) are devastating neurodegenerative disorders with no effective treatments and limited research funding. Congressional advocacy for these rare diseases could accelerate research into tau protein pathology and alpha-synuclein dysfunction, potentially benefiting broader neurodegenerative disease understanding. Clinical Summary CurePSP organized a bipartisan congressional briefing to advocate for increased research funding for three rare neurodegenerative diseases: PSP, CBD, and MSA. These conditions collectively affect tens of thousands of Americans and share pathological features including abnormal protein aggregation (tau in PSP and CBD, alpha-synuclein in MSA). All three diseases have rapid progression, poor prognosis, and no disease-modifying treatments. The briefing aimed to raise awareness about research needs and potential therapeutic targets. Dr. Caplan’s Take “While this briefing focuses on neurological CBD rather than cannabidiol, it highlights how rare disease advocacy can drive research funding. The tau and alpha-synuclein pathways these diseases target may eventually inform broader neurodegenerative therapeutics.” Clinical Perspective 🧠 Clinicians should be aware that PSP, CBD, and MSA remain clinical diagnoses with limited biomarkers and no proven treatments beyond symptomatic management. Patients with these conditions may benefit from specialized movement disorder centers and clinical trial participation. The advocacy effort may eventually yield research advances applicable to more common neurodegenerative diseases. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20CurePSP%20Convenes%20Bipartisan%20Congressional%20Briefing%20to%20Advance%20PSP%2C%20CBD%20and%20MSA%20R...%20%40drcaplan&url=https%3A//www.morningstar.com/news/pr-newswire/20260330dc21382/curepsp-convenes-bipartisan-congressional-briefing-to-advance-psp-cbd-and-msa-research)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.morningstar.com/news/pr-newswire/20260330dc21382/curepsp-convenes-bipartisan-congressional-briefing-to-advance-psp-cbd-and-msa-research)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20CurePSP%20Convenes%20Bipartisan%20Congressional%20Briefing%20to%20Advance%20PSP%2C%20CBD%20and%20MSA%20R...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.morningstar.com/news/pr-newswire/20260330dc21382/curepsp-convenes-bipartisan-congressional-briefing-to-advance-psp-cbd-and-msa-research)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.morningstar.com/news/pr-newswire/20260330dc21382/curepsp-convenes-bipartisan-congressional-briefing-to-advance-psp-cbd-and-msa-research](https://www.morningstar.com/news/pr-newswire/20260330dc21382/curepsp-convenes-bipartisan-congressional-briefing-to-advance-psp-cbd-and-msa-research) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis research?](#What_is_the_clinical_relevance_rating_for_this_cannabis_research) - [What medical conditions does this cannabis research focus on?](#What_medical_conditions_does_this_cannabis_research_focus_on) - [Is this research advocacy or clinical study data?](#Is_this_research_advocacy_or_clinical_study_data) - [Why is this cannabis news considered “new” and noteworthy?](#Why_is_this_cannabis_news_considered_8220new8221_and_noteworthy) - [Who should pay attention to this cannabis research update?](#Who_should_pay_attention_to_this_cannabis_research_update) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis research? This research has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What medical conditions does this cannabis research focus on? The research primarily focuses on neurodegenerative diseases and movement disorders. It also relates to rare disease conditions that may benefit from [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). #### Is this research advocacy or clinical study data? Based on the tags, this appears to be research advocacy content rather than completed [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/). It likely discusses the need for more research or policy changes in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) for neurological conditions. #### Why is this cannabis news considered “new” and noteworthy? The article is marked as “New” content with notable clinical interest, suggesting recent developments in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) for neurological conditions. These emerging findings warrant close monitoring by the medical community. #### Who should pay attention to this cannabis research update? Healthcare professionals treating patients with neurodegenerative diseases, movement disorders, and rare conditions should monitor this research. Clinicians involved in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and neurological care would find this particularly relevant. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CurePSP Convenes Bipartisan Congressional Briefing to Advance PSP, CBD and MSA Research”, “url”: “https://www.morningstar.com/news/pr-newswire/20260330dc21382/curepsp-convenes-bipartisan-congressional-briefing-to-advance-psp-cbd-and-msa-research”, “datePublished”: “2026-03-30T15:01:07Z”, “about”: “curepsp convenes bipartisan congressional briefing advance”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Corticobasal Degeneration | Pacific Neuroscience Institute](https://cedclinic.com/corticobasal-degeneration-neuroprotection-cedclinic/) Learn about corticobasal degeneration, a rare neurodegenerative disorder related to PSP and MSA, including symptoms and current research. [Explore Corticobasal Degeneration](https://cedclinic.com/corticobasal-degeneration-neuroprotection-cedclinic/) [FDA-Approved CBD Drug Shows Early Promise in Anorexia Patients](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) Discover emerging [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on CBD's therapeutic potential, highlighting the importance of advancing cannabinoid-based treatments. [Read About CBD Research](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) [New research project to explore how women with MS experience menopause](https://cedclinic.com/menopause-multiple-sclerosis-research/) Understand ongoing research addressing neurological conditions and symptom management in women with multiple sclerosis. [Learn About MS Research](https://cedclinic.com/menopause-multiple-sclerosis-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).